Bioeel in 2022 generated turnover worth around RON686.4 million (EUR139.5 million) at group level, up 22% from the previous year, in line with ZF calculations.
„This year, a possible challenging situation on the market is likely to be brought about by the price policy in Romania, which in 2022 upended the procurement of certain molecules. For 2023, our estimates envisage 10-15% market growth from 2022,” Daniela Ciulei, Bioeel CEO, told ZF Transilvania.
The company in 2022 invested around RON3.3 million in equipment, technology, digitalization and security. In 2023, it plans to continue investments in tehnology, equipment, digitalization, with RON4.5 million earmarked for the projects.
Bioeel also wants to complete the acquisition of an around 4,000-sqm logistic center.
Bioeel group ended 2022 with 282 employees and plans to recruit further in 2023.
(English version by Catalina Apostoiu)